Inositol
•Last Updated: February 1 2023
Inositol refers to a group of molecules that are involved in various regulatory and metabolic processes. The most commonly supplemented forms of inositol are Myo-inositol and D-chiro-inositol, but all forms are interchangeably referred to as inositol. It’s best known for its effects on insulin resistance and is often supplemented in the context of polycystic ovarian syndrome (PCOS).
Inositol is most often used for
Last Updated: February 1 2023
Inositol refers to a group of molecules that are structurally similar to glucose and are involved in cellular signaling. A majority of inositol supplementation uses the myo-inositol form, as it is the most plentiful type of inositol found in the body.[187] Low concentrations of myo-inositol is found in dietary foods, mainly bran and seeds.[188]
Inositol shows promise for treating insulin resistance by restoring insulin sensitivity and is commonly used for management of PCOS in women.[189] PCOS is a condition associated with abnormalities in glucose metabolism, including reduced insulin sensitivity and elevated fasting blood glucose.[190] Studies have shown that a potential mechanism for insulin deficiency in PCOS is a deficiency in inositol in inositolphosphoglycan mediators and that administration of D-chiro-inositol could be beneficial.[191] Myo-inositol and its role as a second messenger is believed to improve insulin sensitivity and increase intracellular glucose uptake.[192]
Inositol may also have potential benefits as an anxiolytic. Inositol was initially found to exhibit anxiety-reducing effects in animal studies, and its anxiolytic effects were more notable in the context of stressors perceived as more significant than mild stressors.[193][194] Human studies comparing supplementation with inositol to the SSRI fluvoxamine showed that inositol was as effective in reducing symptoms of anxiety as fluvoxamine.[195]
In general, up to 12 grams of inositol per day is safe to ingest, with some gastrointestinal upset associated with higher doses.[196]
Note that Inositol is also known as:
- Myoinositol
- Cyclohexanehexol
- 6-cyclohexanehexol
- 1 2 3 4 5 6-cyclohexanehexol
Inositol should not be confused with:
- D-pinitol (structurally related)
For the treatment of polycystic ovarian syndrome (PCOS), myo-inositol is taken in the range of 200-4,000mg once daily before breakfast; the higher dose seems to be used more often and seems more effective.
Neurological usage of inositol tends to require higher doses, and while antidepressant effects have been noted as low as 6g at times the standard dose is between 14-18g daily.
If using a soft gel formulation rather than powdered myo-inositol, then only 30% of the same dose is required to be equivalent. This would mean the 14-18g range for psychopharmacological effects is now reduced to 4.2-5.4g of myo-inositol soft gels.
What works and what doesn't?
Unlock the full potential of Examine
Latest ResearchRead all studies
1.^Michell RHThe multiplying roles of inositol lipids and phosphates in cell control processesEssays Biochem.(1997)
2.^Parthasarathy R, Eisenberg F JrThe inositol phospholipids: a stereochemical view of biological activityBiochem J.(1986 Apr 15)
3.^Kaiser LG, Schuff N, Cashdollar N, Weiner MWScyllo-inositol in normal aging human brain: 1H magnetic resonance spectroscopy study at 4 TeslaNMR Biomed.(2005 Feb)
4.^Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM; ELND005-AD201 InvestigatorsA phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer diseaseNeurology.(2011 Sep 27)
5.^Holub BJThe nutritional significance, metabolism, and function of myo-inositol and phosphatidylinositol in health and diseaseAdv Nutr Res.(1982)
6.^Clements RS Jr, Reynertson RMyoinositol metabolism in diabetes mellitus. Effect of insulin treatmentDiabetes.(1977 Mar)
7.^Clements RS Jr, Darnell BMyo-inositol content of common foods: development of a high-myo-inositol dietAm J Clin Nutr.(1980 Sep)
8.^Dang NT, Mukai R, Yoshida K, Ashida HD-pinitol and myo-inositol stimulate translocation of glucose transporter 4 in skeletal muscle of C57BL/6 miceBiosci Biotechnol Biochem.(2010)
11.^Draskovic P, Saiardi A, Bhandari R, Burton A, Ilc G, Kovacevic M, Snyder SH, Podobnik MInositol hexakisphosphate kinase products contain diphosphate and triphosphate groupsChem Biol.(2008 Mar)
12.^Mulugu S, Bai W, Fridy PC, Bastidas RJ, Otto JC, Dollins DE, Haystead TA, Ribeiro AA, York JDA conserved family of enzymes that phosphorylate inositol hexakisphosphateScience.(2007 Apr 6)
15.^Irvine RF, Schell MJBack in the water: the return of the inositol phosphatesNat Rev Mol Cell Biol.(2001 May)
16.^Croze ML, Soulage COPotential role and therapeutic interests of myo-inositol in metabolic diseasesBiochimie.(2013 Jun 10)
17.^Shaldubina A, Stahl Z, Furszpan M, Regenold WT, Shapiro J, Belmaker RH, Bersudsky YInositol deficiency diet and lithium effectsBipolar Disord.(2006 Apr)
18.^Eisenberg F Jr, Parthasarathy RMeasurement of biosynthesis of myo-inositol from glucose 6-phosphateMethods Enzymol.(1987)
19.^Deranieh RM, Greenberg ML, Le Calvez PB, Mooney MC, Migaud MEProbing myo-inositol 1-phosphate synthase with multisubstrate adductsOrg Biomol Chem.(2012 Dec 28)
20.^Asplin I, Galasko G, Larner Jchiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjectsProc Natl Acad Sci U S A.(1993 Jul 1)
21.^Kennington AS, Hill CR, Craig J, Bogardus C, Raz I, Ortmeyer HK, Hansen BC, Romero G, Larner JLow urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitusN Engl J Med.(1990 Aug 9)
22.^Scioscia M, Kunjara S, Gumaa K, McLean P, Rodeck CH, Rademacher TWUrinary excretion of inositol phosphoglycan P-type in gestational diabetes mellitusDiabet Med.(2007 Nov)
23.^Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JEAltered D-chiro-inositol urinary clearance in women with polycystic ovary syndromeDiabetes Care.(2006 Feb)
24.^Baillargeon JP, Nestler JE, Ostlund RE, Apridonidze T, Diamanti-Kandarakis EGreek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolismHum Reprod.(2008 Jun)
25.^Stull AJ, Thyfault JP, Haub MD, Ostlund RE Jr, Campbell WWRelationships between urinary inositol excretions and whole-body glucose tolerance and skeletal muscle insulin receptor phosphorylationMetabolism.(2008 Nov)
26.^Larner J, Craig JWUrinary myo-inositol-to-chiro-inositol ratios and insulin resistanceDiabetes Care.(1996 Jan)
27.^Minozzi M, Nordio M, Pajalich RThe Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patientsEur Rev Med Pharmacol Sci.(2013 Feb)
28.^Colazingari S, Treglia M, Najjar R, Bevilacqua AThe combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trialArch Gynecol Obstet.(2013 May 25)
29.^Coady MJ, Wallendorff B, Gagnon DG, Lapointe JYIdentification of a novel Na+/myo-inositol cotransporterJ Biol Chem.(2002 Sep 20)
30.^Ostlund RE Jr, Seemayer R, Gupta S, Kimmel R, Ostlund EL, Sherman WRA stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells. Identification with D-chiro-{3-3H}inositolJ Biol Chem.(1996 Apr 26)
32.^Carlomagno G, De Grazia S, Unfer V, Manna FMyo-inositol in a new pharmaceutical form: a step forward to a broader clinical useExpert Opin Drug Deliv.(2012 Mar)
33.^Gianfranco C, Vittorio U, Silvia B, Francesco DMyo-inositol in the treatment of premenstrual dysphoric disorderHum Psychopharmacol.(2011 Oct)
34.^Larner JD-chiro-inositol--its functional role in insulin action and its deficit in insulin resistanceInt J Exp Diabetes Res.(2002)
35.^Sun TH, Heimark DB, Nguygen T, Nadler JL, Larner JBoth myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controlsBiochem Biophys Res Commun.(2002 May 10)
36.^Yamashita Y, Yamaoka M, Hasunuma T, Ashida H, Yoshida KDetection of orally administered inositol stereoisomers in mouse blood plasma and their effects on translocation of glucose transporter 4 in skeletal muscle cellsJ Agric Food Chem.(2013 May 22)
37.^Kofman O, Agam G, Shapiro J, Spencer AChronic dietary inositol enhances locomotor activity and brain inositol levels in ratsPsychopharmacology (Berl).(1998 Oct)
38.^Agam G, Shapiro Y, Bersudsky Y, Kofman O, Belmaker RHHigh-dose peripheral inositol raises brain inositol levels and reverses behavioral effects of inositol depletion by lithiumPharmacol Biochem Behav.(1994 Oct)
39.^Patishi Y, Lubrich B, Berger M, Kofman O, van Calker D, Belmaker RHDifferential uptake of myo-inositol in vivo into rat brain areasEur Neuropsychopharmacol.(1996 Mar)
41.^Kofman O, Sherman WR, Katz V, Belmaker RHRestoration of brain myo-inositol levels in rats increases latency to lithium-pilocarpine seizuresPsychopharmacology (Berl).(1993)
42.^Levine J, Rapaport A, Lev L, Bersudsky Y, Kofman O, Belmaker RH, Shapiro J, Agam GInositol treatment raises CSF inositol levelsBrain Res.(1993 Nov 5)
43.^Shimon H, Agam G, Belmaker RH, Hyde TM, Kleinman JEReduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorderAm J Psychiatry.(1997 Aug)
44.^Manji HK, Bersudsky Y, Chen G, Belmaker RH, Potter WZModulation of protein kinase C isozymes and substrates by lithium: the role of myo-inositolNeuropsychopharmacology.(1996 Oct)
45.^Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RHDouble-blind, controlled trial of inositol treatment of depressionAm J Psychiatry.(1995 May)
46.^Levine J, Barak Y, Kofman O, Belmaker RHFollow-up and relapse analysis of an inositol study of depressionIsr J Psychiatry Relat Sci.(1995)
47.^Gelber D, Levine J, Belmaker RHEffect of inositol on bulimia nervosa and binge eatingInt J Eat Disord.(2001 Apr)
48.^Nemets B, Mishory A, Levine J, Belmaker RHInositol addition does not improve depression in SSRI treatment failuresJ Neural Transm.(1999)
49.^Levine J, Mishori A, Susnosky M, Martin M, Belmaker RHCombination of inositol and serotonin reuptake inhibitors in the treatment of depressionBiol Psychiatry.(1999 Feb 1)
51.^Zukov I, Ptácek R, Raboch J, Domluvilová D, Kuzelová H, Fischer S, Kozelek PPremenstrual dysphoric disorder--review of actual findings about mental disorders related to menstrual cycle and possibilities of their therapyPrague Med Rep.(2010)
52.^Nemets B, Talesnick B, Belmaker RH, Levine JMyo-inositol has no beneficial effect on premenstrual dysphoric disorderWorld J Biol Psychiatry.(2002 Jul)
53.^Chengappa KN, Levine J, Gershon S, Mallinger AG, Hardan A, Vagnucci A, Pollock B, Luther J, Buttenfield J, Verfaille S, Kupfer DJInositol as an add-on treatment for bipolar depressionBipolar Disord.(2000 Mar)
54.^Sarris J, Kavanagh DJ, Byrne GAdjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepinesJ Psychiatr Res.(2010 Jan)
55.^Qureshi NA, Al-Bedah AMMood disorders and complementary and alternative medicine: a literature reviewNeuropsychiatr Dis Treat.(2013)
56.^Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GSTreatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidoneAm J Psychiatry.(2006 Feb)
57.^Cohen H, Kotler M, Kaplan Z, Matar MA, Kofman O, Belmaker RHInositol has behavioral effects with adaptation after chronic administrationJ Neural Transm.(1997)
58.^Einat H, Elkabaz-Shwortz Z, Cohen H, Kofman O, Belmaker RHChronic epi-inositol has an anxiolytic-like effect in the plus-maze model in ratsInt J Neuropsychopharmacol.(1998 Jul)
59.^Kofman O, Einat H, Cohen H, Tenne H, Shoshana CThe anxiolytic effect of chronic inositol depends on the baseline level of anxietyJ Neural Transm.(2000)
60.^Palatnik A, Frolov K, Fux M, Benjamin JDouble-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorderJ Clin Psychopharmacol.(2001 Jun)
61.^Benjamin J, Nemetz H, Fux M, Bleichman I, Agam GAcute inositol does not attenuate m-CPP-induced anxiety, mydriasis and endocrine effects in panic disorderJ Psychiatr Res.(1997 Jul-Aug)
62.^Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RHDouble-blind, placebo-controlled, crossover trial of inositol treatment for panic disorderAm J Psychiatry.(1995 Jul)
63.^Kaplan Z, Amir M, Swartz M, Levine JInositol treatment of post-traumatic stress disorderAnxiety.(1996)
64.^Levine J, Goldberger I, Rapaport A, Schwartz M, Schield C, Elizur A, Belmaker RH, Shapiro J, Agam GCSF inositol in schizophrenia and high-dose inositol treatment of schizophreniaEur Neuropsychopharmacol.(1994 Dec)
65.^Levine J, Umansky R, Ezrielev G, Belmaker RHLack of effect of inositol treatment in chronic schizophreniaBiol Psychiatry.(1993 Apr 15-May 1)
66.^Fux M, Levine J, Aviv A, Belmaker RHInositol treatment of obsessive-compulsive disorderAm J Psychiatry.(1996 Sep)
67.^Seedat S, Stein DJInositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trialInt Clin Psychopharmacol.(1999 Nov)
68.^Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression.()
69.^Kofman O, Bersudsky Y, Vinnitsky I, Alpert C, Belmaker RHThe effect of peripheral inositol injection on rat motor activity models of depressionIsr J Med Sci.(1993 Sep)
70.^Levine J, Pomerantz T, Stier S, Belmaker RHLack of effect of 6 g inositol treatment of post-ECT cognitive function in humansJ Psychiatr Res.(1995 Nov-Dec)
71.^Michaelis T, Helms G, Merboldt KD, Hänicke W, Bruhn H, Frahm JIdentification of Scyllo-inositol in proton NMR spectra of human brain in vivoNMR Biomed.(1993 Jan-Feb)
72.^Frahm J, Bruhn H, Hänicke W, Merboldt KD, Mursch K, Markakis ELocalized proton NMR spectroscopy of brain tumors using short-echo time STEAM sequencesJ Comput Assist Tomogr.(1991 Nov-Dec)
73.^Seaquist ER, Gruetter RIdentification of a high concentration of scyllo-inositol in the brain of a healthy human subject using 1H- and 13C-NMRMagn Reson Med.(1998 Feb)
74.^Fenili D, Brown M, Rappaport R, McLaurin JProperties of scyllo-inositol as a therapeutic treatment of AD-like pathologyJ Mol Med (Berl).(2007 Jun)
75.^McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PEInositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicityJ Biol Chem.(2000 Jun 16)
76.^Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BLNatural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathwayJ Neurosci.(2007 Mar 14)
77.^McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SS, Mount HT, Fraser PE, Westaway D, St George-Hyslop PCyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse modelNat Med.(2006 Jul)
78.^Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, Walsh DM, Selkoe DJOrally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomersAnn Neurol.(2006 Dec)
79.^Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men.()
80.^Barak Y, Levine J, Glasman A, Elizur A, Belmaker RHInositol treatment of Alzheimer's disease: a double blind, cross-over placebo controlled trialProg Neuropsychopharmacol Biol Psychiatry.(1996 May)
81.^Levine J, Aviram A, Holan A, Ring A, Barak Y, Belmaker RHInositol treatment of autismJ Neural Transm.(1997)
82.^Brosche TPlasmalogen levels in serum from patients with impaired carbohydrate or lipid metabolism and in elderly subjects with normal metabolic valuesArch Gerontol Geriatr.(2001 Jun)
83.^Maeba R, Maeda T, Kinoshita M, Takao K, Takenaka H, Kusano J, Yoshimura N, Takeoka Y, Yasuda D, Okazaki T, Teramoto TPlasmalogens in human serum positively correlate with high- density lipoprotein and decrease with agingJ Atheroscler Thromb.(2007 Feb)
84.^Bräutigam C, Engelmann B, Reiss D, Reinhardt U, Thiery J, Richter WO, Brosche TPlasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresisAtherosclerosis.(1996 Jan 5)
85.^Maeba R, Ueta NDetermination of choline and ethanolamine plasmalogens in human plasma by HPLC using radioactive triiodide (1-) ion (125I3-)Anal Biochem.(2004 Aug 1)
86.^Maeba R, Hara H, Ishikawa H, Hayashi S, Yoshimura N, Kusano J, Takeoka Y, Yasuda D, Okazaki T, Kinoshita M, Teramoto TMyo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndromeJ Nutr Sci Vitaminol (Tokyo).(2008 Jun)
88.^Caro HN, Kunjara S, Rademacher TW, León Y, Jones DR, Avila MA, Varela-Nieto IIsolation and partial characterisation of insulin-mimetic inositol phosphoglycans from human liverBiochem Mol Med.(1997 Aug)
89.^McLean P, Kunjara S, Greenbaum AL, Gumaa K, López-Prados J, Martin-Lomas M, Rademacher TWReciprocal control of pyruvate dehydrogenase kinase and phosphatase by inositol phosphoglycans. Dynamic state set by "push-pull" systemJ Biol Chem.(2008 Nov 28)
90.^Roche TE, Baker JC, Yan X, Hiromasa Y, Gong X, Peng T, Dong J, Turkan A, Kasten SADistinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoformsProg Nucleic Acid Res Mol Biol.(2001)
91.^Denton RM, McCormack JG, Rutter GA, Burnett P, Edgell NJ, Moule SK, Diggle TAThe hormonal regulation of pyruvate dehydrogenase complexAdv Enzyme Regul.(1996)
92.^Harris RA, Bowker-Kinley MM, Huang B, Wu PRegulation of the activity of the pyruvate dehydrogenase complexAdv Enzyme Regul.(2002)
93.^Cohen PThe role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal LectureEur J Biochem.(2001 Oct)
95.^Kunjara S, Wang DY, Greenbaum AL, McLean P, Kurtz A, Rademacher TWInositol phosphoglycans in diabetes and obesity: urinary levels of IPG A-type and IPG P-type, and relationship to pathophysiological changesMol Genet Metab.(1999 Dec)
96.^Shashkin PN, Shashkina EF, Fernqvist-Forbes E, Zhou YP, Grill V, Katz AInsulin mediators in man: effects of glucose ingestion and insulin resistanceDiabetologia.(1997 May)
97.^Larner JD-chiro-inositol in insulin action and insulin resistance-old-fashioned biochemistry still at workIUBMB Life.(2001 Mar)
98.^Dugani CB, Klip AGlucose transporter 4: cycling, compartments and controversiesEMBO Rep.(2005 Dec)
99.^Farese RV, Sajan MP, Standaert MLAtypical protein kinase C in insulin action and insulin resistanceBiochem Soc Trans.(2005 Apr)
100.^Ng Y, Ramm G, Lopez JA, James DERapid activation of Akt2 is sufficient to stimulate GLUT4 translocation in 3T3-L1 adipocytesCell Metab.(2008 Apr)
101.^Randhawa VK, Ishikura S, Talior-Volodarsky I, Cheng AW, Patel N, Hartwig JH, Klip AGLUT4 vesicle recruitment and fusion are differentially regulated by Rac, AS160, and Rab8A in muscle cellsJ Biol Chem.(2008 Oct 3)
102.^Ijuin T, Takenawa TRegulation of insulin signaling and glucose transporter 4 (GLUT4) exocytosis by phosphatidylinositol 3,4,5-trisphosphate (PIP3) phosphatase, skeletal muscle, and kidney enriched inositol polyphosphate phosphatase (SKIP)J Biol Chem.(2012 Mar 2)
103.^Rameh LE, Cantley LCThe role of phosphoinositide 3-kinase lipid products in cell functionJ Biol Chem.(1999 Mar 26)
104.^Bryant NJ, Govers R, James DERegulated transport of the glucose transporter GLUT4Nat Rev Mol Cell Biol.(2002 Apr)
105.^Mikoshiba KIP3 receptor/Ca2+ channel: from discovery to new signaling conceptsJ Neurochem.(2007 Sep)
106.^Tanti JF, Grémeaux T, Grillo S, Calleja V, Klippel A, Williams LT, Van Obberghen E, Le Marchand-Brustel YOverexpression of a constitutively active form of phosphatidylinositol 3-kinase is sufficient to promote Glut 4 translocation in adipocytesJ Biol Chem.(1996 Oct 11)
107.^Kotani K, Carozzi AJ, Sakaue H, Hara K, Robinson LJ, Clark SF, Yonezawa K, James DE, Kasuga MRequirement for phosphoinositide 3-kinase in insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytesBiochem Biophys Res Commun.(1995 Apr 6)
108.^Kanai F, Ito K, Todaka M, Hayashi H, Kamohara S, Ishii K, Okada T, Hazeki O, Ui M, Ebina YInsulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3-kinaseBiochem Biophys Res Commun.(1993 Sep 15)
109.^Furuichi T, Kohda K, Miyawaki A, Mikoshiba KIntracellular channelsCurr Opin Neurobiol.(1994 Jun)
110.^Iwai M, Tateishi Y, Hattori M, Mizutani A, Nakamura T, Futatsugi A, Inoue T, Furuichi T, Michikawa T, Mikoshiba KMolecular cloning of mouse type 2 and type 3 inositol 1,4,5-trisphosphate receptors and identification of a novel type 2 receptor splice variantJ Biol Chem.(2005 Mar 18)
111.^Co-expression in vertebrate tissues and cell lines of multiple inositol 1,4,5-trisphosphate (InsP3) receptors with distinct affinities for InsP3.()
112.^Nakashima N, Sharma PM, Imamura T, Bookstein R, Olefsky JMThe tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytesJ Biol Chem.(2000 Apr 28)
113.^Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ, Sherwin R, Devaskar S, Lesche R, Magnuson MA, Wu HLiver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity {corrected}Proc Natl Acad Sci U S A.(2004 Feb 17)
114.^Kurlawalla-Martinez C, Stiles B, Wang Y, Devaskar SU, Kahn BB, Wu HInsulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissueMol Cell Biol.(2005 Mar)
115.^Wada T, Sasaoka T, Funaki M, Hori H, Murakami S, Ishiki M, Haruta T, Asano T, Ogawa W, Ishihara H, Kobayashi MOverexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activityMol Cell Biol.(2001 Mar)
116.^Sasaoka T, Hori H, Wada T, Ishiki M, Haruta T, Ishihara H, Kobayashi MSH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubesDiabetologia.(2001 Oct)
117.^Sleeman MW, Wortley KE, Lai KM, Gowen LC, Kintner J, Kline WO, Garcia K, Stitt TN, Yancopoulos GD, Wiegand SJ, Glass DJAbsence of the lipid phosphatase SHIP2 confers resistance to dietary obesityNat Med.(2005 Feb)
118.^Ijuin T, Takenawa TSKIP negatively regulates insulin-induced GLUT4 translocation and membrane ruffle formationMol Cell Biol.(2003 Feb)
119.^Ijuin T, Yu YE, Mizutani K, Pao A, Tateya S, Tamori Y, Bradley A, Takenawa TIncreased insulin action in SKIP heterozygous knockout miceMol Cell Biol.(2008 Sep)
120.^Kong AM, Horan KA, Sriratana A, Bailey CG, Collyer LJ, Nandurkar HH, Shisheva A, Layton MJ, Rasko JE, Rowe T, Mitchell CAPhosphatidylinositol 3-phosphate {PtdIns3P} is generated at the plasma membrane by an inositol polyphosphate 5-phosphatase: endogenous PtdIns3P can promote GLUT4 translocation to the plasma membraneMol Cell Biol.(2006 Aug)
121.^Taguchi A, Emoto M, Okuya S, Fukuda N, Nakamori Y, Miyazaki M, Miyamoto S, Tanabe K, Aburatani H, Oka Y, Tanizawa YIdentification of Glypican3 as a novel GLUT4-binding proteinBiochem Biophys Res Commun.(2008 May 16)
122.^Kawa JM, Taylor CG, Przybylski RBuckwheat concentrate reduces serum glucose in streptozotocin-diabetic ratsJ Agric Food Chem.(2003 Dec 3)
124.^Rat L6 myotubes as an in vitro model system to study GLUT4-dependent glucose uptake stimulated by inositol derivatives.()
125.^Giordano D, Corrado F, Santamaria A, Quattrone S, Pintaudi B, Di Benedetto A, D'Anna REffects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled studyMenopause.(2011 Jan)
126.^Santamaria A, Giordano D, Corrado F, Pintaudi B, Interdonato ML, Vieste GD, Benedetto AD, D'Anna ROne-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndromeClimacteric.(2012 Oct)
127.^Corrado F, D'Anna R, Di Vieste G, Giordano D, Pintaudi B, Santamaria A, Di Benedetto AThe effect of myoinositol supplementation on insulin resistance in patients with gestational diabetesDiabet Med.(2011 Aug)
128.^D'Anna R, Di Benedetto V, Rizzo P, Raffone E, Interdonato ML, Corrado F, Di Benedetto AMyo-inositol may prevent gestational diabetes in PCOS womenGynecol Endocrinol.(2012 Jun)
129.^Chau JF, Lee MK, Law JW, Chung SK, Chung SSSodium/myo-inositol cotransporter-1 is essential for the development and function of the peripheral nervesFASEB J.(2005 Nov)
130.^Grant PS, Lipscomb DHow often do we ask about erectile dysfunction in the diabetes review clinic? Development of a neuropathy screening toolActa Diabetol.(2009 Dec)
131.^Hecht MJ, Neundörfer B, Kiesewetter F, Hilz MJNeuropathy is a major contributing factor to diabetic erectile dysfunctionNeurol Res.(2001 Sep)
132.^Agostini R, Rossi F, Pajalich RMyoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled studyEur Rev Med Pharmacol Sci.(2006 Sep-Oct)
133.^Gerli S, Mignosa M, Di Renzo GCEffects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trialEur Rev Med Pharmacol Sci.(2003 Nov-Dec)
134.^Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, Campedelli A, Simoncini T, Artini PGDifferential insulin response to myo-inositol administration in obese polycystic ovary syndrome patientsGynecol Endocrinol.(2012 Dec)
135.^Donà G, Sabbadin C, Fiore C, Bragadin M, Giorgino FL, Ragazzi E, Clari G, Bordin L, Armanini DInositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndromeEur J Endocrinol.(2012 Apr)
136.^Nordio M, Proietti EThe combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation aloneEur Rev Med Pharmacol Sci.(2012 May)
137.^Gerli S, Papaleo E, Ferrari A, Di Renzo GCRandomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOSEur Rev Med Pharmacol Sci.(2007 Sep-Oct)
139.^Daniilidis A, Dinas KLong term health consequences of polycystic ovarian syndrome: a review analysisHippokratia.(2009 Apr)
140.^Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BCPCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factorsBJOG.(2006 Oct)
141.^Stankiewicz M, Norman RDiagnosis and management of polycystic ovary syndrome: a practical guideDrugs.(2006)
142.^Cascella T, Palomba S, De Sio I, Manguso F, Giallauria F, De Simone B, Tafuri D, Lombardi G, Colao A, Orio FVisceral fat is associated with cardiovascular risk in women with polycystic ovary syndromeHum Reprod.(2008 Jan)
143.^Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, Caruso A, Lanzone AImpact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndromeMetabolism.(1999 Feb)
145.^Unfer V, Carlomagno G, Dante G, Facchinetti FEffects of myo-inositol in women with PCOS: a systematic review of randomized controlled trialsGynecol Endocrinol.(2012 Jul)
146.^Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, Cela VEndocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized studyGynecol Endocrinol.(2013 Apr)
147.^Costantino D, Minozzi G, Minozzi E, Guaraldi CMetabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trialEur Rev Med Pharmacol Sci.(2009 Mar-Apr)
148.^Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VMMyo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndromeGynecol Endocrinol.(2008 Mar)
149.^Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari AMyo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation inductionGynecol Endocrinol.(2007 Dec)
150.^Ciotta L, Stracquadanio M, Pagano I, Carbonaro A, Palumbo M, Gulino FEffects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trialEur Rev Med Pharmacol Sci.(2011 May)
151.^Lisi F, Carfagna P, Oliva MM, Rago R, Lisi R, Poverini R, Manna C, Vaquero E, Caserta D, Raparelli V, Marci R, Moscarini MPretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot studyReprod Biol Endocrinol.(2012 Jul 23)
152.^Raffone E, Rizzo P, Benedetto VInsulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS womenGynecol Endocrinol.(2010 Apr)
153.^Hazell AS, Butterworth RFHepatic encephalopathy: An update of pathophysiologic mechanismsProc Soc Exp Biol Med.(1999 Nov)
154.^Lockwood AH, Yap EW, Wong WHCerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathyJ Cereb Blood Flow Metab.(1991 Mar)
155.^Shawcross DL, Balata S, Olde Damink SW, Hayes PC, Wardlaw J, Marshall I, Deutz NE, Williams R, Jalan RLow myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemiaAm J Physiol Gastrointest Liver Physiol.(2004 Sep)
156.^Lien YH, Michaelis T, Moats RA, Ross BDScyllo-inositol depletion in hepatic encephalopathyLife Sci.(1994)
157.^Binesh N, Huda A, Thomas MA, Wyckoff N, Bugbee M, Han S, Rasgon N, Davanzo P, Sayre J, Guze B, Martin P, Fawzy FHepatic encephalopathy: a neurochemical, neuroanatomical, and neuropsychological studyJ Appl Clin Med Phys.(2006 Winter)
158.^Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Galbraith AR, Steele VE, Kelloff GJChemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositolCarcinogenesis.(2000 Feb)
159.^Hecht SS, Kenney PM, Wang M, Upadhyaya PDose-response study of myo-inositol as an inhibitor of lung tumorigenesis induced in A/J mice by benzoCancer Lett.(2001 Jun 10)
160.^Estensen RD, Wattenberg LWStudies of chemopreventive effects of myo-inositol on benzo{a}pyrene-induced neoplasia of the lung and forestomach of female A/J miceCarcinogenesis.(1993 Sep)
161.^Lam S, McWilliams A, LeRiche J, MacAulay C, Wattenberg L, Szabo EA phase I study of myo-inositol for lung cancer chemopreventionCancer Epidemiol Biomarkers Prev.(2006 Aug)
162.^Zacchè MM, Caputo L, Filippis S, Zacchè G, Dindelli M, Ferrari AEfficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndromeGynecol Endocrinol.(2009 Aug)
164.^Tsankov N, Angelova I, Kazandjieva JDrug-induced psoriasis. Recognition and managementAm J Clin Dermatol.(2000 May-Jun)
165.^Williams RS, Cheng L, Mudge AW, Harwood AJA common mechanism of action for three mood-stabilizing drugsNature.(2002 May 16)
167.^Allan SJ, Kavanagh GM, Herd RM, Savin JAThe effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trialBr J Dermatol.(2004 May)
168.^Cupisti S, Dittrich R, Binder H, Kajaia N, Hoffmann I, Maltaris T, Beckmann MW, Mueller AInfluence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOSExp Clin Endocrinol Diabetes.(2007 Jun)
169.^Mueller A, Cupisti S, Binder H, Hoffmann I, Kiesewetter F, Beckmann MW, Dittrich REndocrinological markers for assessment of hyperandrogenemia in hirsute womenHorm Res.(2007)
170.^Minozzi M, D'Andrea G, Unfer VTreatment of hirsutism with myo-inositol: a prospective clinical studyReprod Biomed Online.(2008 Oct)
171.^Smith DFLithium orotate, carbonate and chloride: pharmacokinetics, polyuria in ratsBr J Pharmacol.(1976 Apr)
172.^Minozzi M, Costantino D, Guaraldi C, Unfer VThe effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndromeGynecol Endocrinol.(2011 Nov)
173.^Galletta M, Grasso S, Vaiarelli A, Roseff SJBye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation inductionEur Rev Med Pharmacol Sci.(2011 Oct)
175.^Tantivejkul K, Vucenik I, Shamsuddin AMInositol hexaphosphate (IP6) inhibits key events of cancer metastasis: II. Effects on integrins and focal adhesionsAnticancer Res.(2003 Sep-Oct)
177.^Singh RP, Sharma G, Mallikarjuna GU, Dhanalakshmi S, Agarwal C, Agarwal RIn vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factorClin Cancer Res.(2004 Jan 1)
178.^Bohn T, Davidsson L, Walczyk T, Hurrell RFPhytic acid added to white-wheat bread inhibits fractional apparent magnesium absorption in humansAm J Clin Nutr.(2004 Mar)
179.^Larsson M, Rossander-Hulthén L, Sandström B, Sandberg ASImproved zinc and iron absorption from breakfast meals containing malted oats with reduced phytate contentBr J Nutr.(1996 Nov)
180.^Vucenik I, Shamsuddin AMCancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinicJ Nutr.(2003 Nov)
181.^Vucenik I, Shamsuddin AMProtection against cancer by dietary IP6 and inositolNutr Cancer.(2006)
182.^Tantivejkul K, Vucenik I, Eiseman J, Shamsuddin AMInositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancerBreast Cancer Res Treat.(2003 Jun)
183.^Bacić I, Druzijanić N, Karlo R, Skifić I, Jagić SEfficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical studyJ Exp Clin Cancer Res.(2010 Feb 12)
184.^Unfer V, Raffone E, Rizzo P, Buffo SEffect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort studyGynecol Endocrinol.(2011 Nov)
185.^Rizzo P, Raffone E, Benedetto VEffect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trialEur Rev Med Pharmacol Sci.(2010 Jun)
Primary Use
Secondary Use